Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro
|Date||March 18, 2020|
In vitro study demonstrating that hydroxychloroquine is effective in inhibiting SARS-CoV-2 infection by blocking the transport of SARS-CoV-2 from EEs to Els, which is a requirement to release the viral genome. Authors conclude that hydroxychloroquine’s in vitro effect of inhibiting viral replication in combination with its anti-inflammatory function makes the drug a good candidate for treatment of COVID-19.
No major issues identified.
No minor issues identified.
This study demonstrated in vitro efficacy of hydroxychloroquine in blocking a necessary step in viral replication of SARS-CoV-2.
None at this time.